Tags · Clinical
older adults
Sarcopenia risk, polypharmacy and frailty.
Related in this group: HbA1c · lipid panel · eGFR & renal function · liver enzymes · thyroid function · lipase & amylase · inflammatory markers · micronutrients · blood pressure · heart rate · type 2 diabetes · chronic kidney disease
16 topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Adolescents: a distinct evidence base
Adolescents: a distinct evidence base Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of adolescents is wrong? I ask because I have been…
|
3 | 11k | 9h | |
|
Athletes in weight-category sports: a different risk calculus
Athletes in weight-category sports: a different risk calculus — setting out what I have, and where I think it stops being reliable. Something about athletes in weight-category sports does not reconcile and I…
|
+38 | 42 | 6.6k | 1d |
|
Bariatric surgery history: altered anatomy, altered expectations
Posting this under the heading it deserves: Bariatric surgery history: altered anatomy, altered expectations Everything below is what sits behind that. Asking about bariatric surgery history directly, because…
|
+35 | 39 | 486 | 2mo |
|
About the Special populations category
Older adults, pregnancy and pregnancy planning, adolescents, renal and hepatic impairment, bariatric surgery history. This post is a community wiki: any member at trust level 3 or above can edit it, and every…
|
4 | 3k | 4mo | |
|
Hepatic impairment and the absence of data — a second dataset
On the subject in the title: Hepatic impairment and the absence of data — a second dataset Working notes rather than a conclusion. Posting a small dataset on Hepatic impairment. It is mine, it is…
|
2 | 4.3k | 4mo | |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies
Older adults, sarcopenia risk, and the trade-off nobody quantifies — setting out what I have, and where I think it stops being reliable. Older adults: setting out the arithmetic in full, because I have had to…
|
+103 | 109 | 12k | 5mo |
|
Second pass at: Pregnancy and pregnancy planning: contraindication and washout
Second pass at: Pregnancy and pregnancy planning: contraindication and washout Writing it up because I had to work it out twice and would rather nobody else did. Something about Pregnancy and pregnancy…
|
+111 | 127 | 1.6k | 6mo |
|
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version
Older adults, sarcopenia risk, and the trade-off nobody quantifies — the long version — setting out what I have, and where I think it stops being reliable. A narrow question about Older adults, deliberately…
|
+64 | 69 | 15k | 7mo |
|
History of disordered eating and why it changes the conversation
History of disordered eating and why it changes the conversation Writing it up because I had to work it out twice and would rather nobody else did. What changes if the standard account of history of…
|
+20 | 24 | 30k | 8mo |
|
Hepatic impairment and the absence of data
Hepatic impairment and the absence of data — setting out what I have, and where I think it stops being reliable. I was wrong about hepatic impairment in a thread last spring and I would like to correct it…
|
+30 | 35 | 32k | 10mo |
|
Follow-up: History of disordered eating and why it changes the conversation
Posting this under the heading it deserves: History of disordered eating and why it changes the conversation Everything below is what sits behind that. What changes if the standard account of History of…
|
+75 | 81 | 23k | 10mo |
|
Coming back to: Bariatric surgery history: altered anatomy, altered expectations
Bariatric surgery history: altered anatomy, altered expectations Writing it up because I had to work it out twice and would rather nobody else did. Bariatric surgery history — I have the observation and I do…
|
2 | 38k | 15mo | |
|
Coming back to: Renal impairment: what the labelling says about dose
Renal impairment: what the labelling says about dose — setting out what I have, and where I think it stops being reliable. Renal impairment — I have the observation and I do not trust my interpretation of it,…
|
+30 | 34 | 48k | 18mo |
|
Renal impairment: what the labelling says about dose
On the subject in the title: Renal impairment: what the labelling says about dose Working notes rather than a conclusion. A methods question rather than a substantive one, about renal impairment. Everyone…
|
4 | 8.9k | 19mo | |
|
People with a low starting BMI: where the evidence stops
Posting this under the heading it deserves: People with a low starting BMI: where the evidence stops Everything below is what sits behind that. Asking about a population rather than about a person. The…
|
+23 | 27 | 5.8k | 19mo |
|
Type 1 diabetes: off-label use and the evidence gap — what changed since
Type 1 diabetes: off-label use and the evidence gap — what changed since — setting out what I have, and where I think it stops being reliable. What changes if the standard account of Type 1 diabetes is wrong?…
|
+68 | 77 | 31k | 20mo |
Sponsored
Janoshik Analytical — independent third-party testingHPLC purity and mass-spectrometric identity on submitted samples, reported with the method stated. The laboratory most often cited in this community’s verification records.Independent testing →
Sponsored
GL Biochem (Shanghai) Ltd. — synthesis, directFounded 1998. ISO 9001 and cGMP certified, over 1,500 staff and 200-plus patents. Custom peptide synthesis and amino acid derivatives, with a batch certificate on every order.Custom synthesis →